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Abstract 
Background & Aims: Inflammatory bowel disease (IBD) scoring systems combine patient-
reported data with physicians’ observations to determine patient outcomes, but these systems 
are believed to have limitations. We used real-world data from a large IBD cohort in 
Switzerland to compare results between patients and healthcare professionals’ from scoring 
systems for Crohn’s disease (CD) and ulcerative colitis (UC).  
Methods: We collected data from the Swiss IBD cohort, beginning in 2006, using 2453 reports 
for 1385 patients (52% female, 58% with CD). During office visits, physicians asked patients 
about signs and symptoms and recorded their answers (health care professional-reported 
outcomes). On a later date, patients received a questionnaire at home (independently of the 
medical visit), complete it, and sent it back to the data center. Patients also completed the short 
form 36 and IBD quality of life (QoL) questionnaires. We calculated Cohen’s kappa (κ) 
statistics to assess the level of agreement in scores between patients and health care 
professionals (∆t between reports collected less than 2 months apart). We used Spearman 
correlation coefficients (r) to compare general well-being (GWB) and QoL scores determined 
by patients vs health care professionals. Our primary aim was to investigate the overall and 
individual level of agreement on signs and symptoms reported by health care professionals vs 
patients. 
Results: The best level of agreement (although moderate) was observed for number of stools 
last week in patients with CD (κ=0.47), and nocturnal diarrhea in patients with UC (κ=0.52). 
Agreement was low on level of abdominal pain (κ=0.31 for patients with CD and κ=0.37 for 
patients with UC) and GWB (κ=0.23 for patients with CD and κ=0.26 for patients with UC). 
Patients reported less severe abdominal pain and worse GWB (CD) or better GWB (UC) than 
that determined by health care professionals. Patient self-rated GWB correlated with IBD 
quality of life (r=0.68 for patients with CD and r=0.70 for patients with UC) and SF-36 physical 
scores (r=0.55 for patients with CD and r=0.60 for patients with UC); there was no correlation 
between health care professional-rated GWB and QoL. 
Conclusion: In a comparison of patient vs health care provider-reported outcomes in a Swiss 
IBD cohort, we found that health care professionals seem to misinterpret patients’ complaints. 
Patients self-rated GWB correlated with QoL scores, indicating that reporting GWB in a single 
question is possible and relevant, but can vary based on how the data are collected. 
KEY WORDS: disease activity index; SF-36; PRO; management 
Introduction 
In inflammatory bowel diseases (IBD), treatment goals are based on clinical, endoscopic, 
biologic, and histologic endpoints1, 2. Signs and symptoms are currently assessed through 
disease activity scores, which consist of a mixture of patient-reported outcomes (PROs) and 
physician’s observations, sometimes complemented by laboratory values or endoscopic 
evaluations. These scores have shown limitations in clinical trials3, mainly because PROs were 
not constructed from patients’ views about their symptoms and health-related quality of life, 
but from clinicians’ interpretations of patients’ views, thus introducing potential bias into PRO 
measures (PROMs). Indeed, PROMs are defined as measures that should ascertain patients’ 
views about their life4, to be reported directly by the patient without interpretation by a clinician 
or anyone else5. Pending the development of such ideal PROs, interim PROs have been 
proposed for use in clinical trials for Crohn’s disease (CD)6 and ulcerative colitis (UC)7. These 
PROs, however, were derived from retrospective data. They are thus not taken directly from 
patient-reported data, and their extraction has not been prospectively validated. 
Tremendous work has been made during the past 5 years to redefine PROs,8-12 both in 
general and more specifically to define a core set of PROs to be used in clinical trials12-15. PRO 
developments have also recently been reported in other chronic inflammatory or gastrointestinal 
(GI) diseases16-18. In IBD, the addition of PROs to clinical scores used by healthcare 
professionals (HCPs) can improve their ability to predict endoscopic remission19. Further, it is 
crucial for the promotion of patient empowerment programs to develop endpoints based on 
information reported by patients themselves and to use these endpoints in clinical trials20, 21.  
Defining symptom-based PROs is important because symptoms remain the central driver 
for patients in their decisions regarding care, potential treatment changes, diet adaptations, and 
healthcare help seeking. PROs will also be central for future self-management programs. Future 
management strategies favor tight control and monitoring of patients22 to target preclinical signs 
of relapse; the goal is to prevent disease progression and achieve better long-term outcomes. 
Thus, treatment and management decisions in IBD call for good translation of scores developed 
in trials into clinical practice, the goal being to use these scores to assess treatment effectiveness. 
In the first stage, the accuracy and practicability of assessing disease activity scores (including 
current PROs) should be determined through real-world data collected in routine settings by 
HCPs involved in regular follow-up visits. This would help to provide insight into the content 
and validity of the items generated from trials to be used in routine clinical practice23.  
Our primary aim was to investigate the overall and individual levels of agreement on the 
signs and symptoms of IBD reported by HCPs and patients. Our secondary aim was to study 
the feasibility of capturing patient-reported information on quality of life through a single 
simple question on general well-being used in activity indexes. 
 
  
Methods 
Patient population 
The Swiss IBD cohort (SIBDC) is a national ongoing prospective cohort of incident and 
prevalent IBD cases that started in November 2006. Patients were recruited through their 
gastroenterologist. Recruitment was open to any gastroenterologist working in a tertiary center, 
regional hospital, or private practice. Patients’ inclusion criteria were the following: being 
diagnosed for at least 2 months or having had at least 1 recurrence of symptoms, diagnosis 
confirmed by radiological or endoscopic and histological findings, living in Switzerland or 
having contracted Swiss healthcare insurance, and being treated for IBD in Switzerland. 
Cohort data 
We used data collected in the framework of the SIBDC to characterize patients and their 
disease. Clinical characteristics and treatments were collected during patients’ yearly medical 
visits by gastroenterologists or trained study nurses (hereafter grouped as HCPs). Annual 
follow-up questionnaires were sent to patients to collect patient-reported data, including 
psychosomatic scores.  
For descriptive purposes, the following were extracted from the SIBDC databases: 
gender, age, age at diagnosis, type of diagnosis (CD or UC), CD disease location (ileal, colonic, 
ileocolonic, upper GI only), UC extension (proctitis, left-sided colitis, pancolitis), history of 
extraintestinal manifestations (EIMs), CD history of perianal fistula, CD history of stenosis, 
and history of therapies. We also collected all items used to calculate disease activity scores, 
namely, the Crohn’s Disease Activity Index (CDAI) for CD (number of soft stools last week, 
abdominal pain, general well-being [GWB], EIMs, antidiarrheal treatment, abdominal mass, 
hematocrit, body weight) and the Modified Truelove and Witts activity index (MTWAI) for 
UC (number of bowel movements per day, nocturnal diarrhea, bloody stools, fecal 
incontinence, abdominal pain/cramping, GWB, antidiarrheal treatment, abdominal tenderness). 
Remission was defined as a CDAI score lower than or equal to 150 for CD, or an MTWAI score 
lower than or equal to 4 for UC. For the CDAI, patients recorded the number of stools 
retrospectively. 
From the self-administered patient questionnaires, we extracted psychometric data on 
general and disease-related quality of life (QoL). We used the Short Form (36) Health Survey 
Questionnaire (SF-36), divided into 2 subscores, the Physical Component Summary score 
(PCS) and the Mental Component Summary score (MCS). The 32-question Inflammatory 
Bowel Diseases Questionnaire (IBDQ) was summed as a total score and divided into 4 
subscores (bowel symptoms, systemic symptoms, emotional function, and social function). 
From 2012 to 2015, we also collected patient-reported information on signs, symptoms, and 
antidiarrheal treatment as follows: number of soft stools last week (number per day and total 
number), nocturnal diarrhea (yes, no), bloody stool frequency (continuous scale from 0% to 
100%), fecal incontinence (yes, no), abdominal pain/cramps (continuous scale from 0 to 4, 
0=never, 4=severe), GWB (continuous scale from 0 to 5, 0=very bad, 5=very well), 
antidiarrheal treatment (yes, no), fever in last 7 days (yes, no), surgery planned in the coming 
weeks (yes, no), EIMs. Patients were asked to complete all questions, regardless of their 
diagnosis. This decision was made from our previous observation that a non-negligible number 
of patients indicated another diagnosis (CD versus UC) than that established by their doctor. 
For this reason, we referred only to the diagnosis confirmed by the physician in the analyses. 
The results presented hereafter were not stratified by disease activity (active versus 
remission). Stratification by disease activity was first performed, but did not show significant 
differences compared with non-stratified analysis. The number of cases for patients with active 
disease was 26 (4.8%) for CD and 31 (16.2%) for UC; thus, the number of cases was low, 
probably due to the difficulty in collecting information from the patient at the time of a flare in 
a real-life situation. We found that kappa values were low regardless of whether patients had 
active or inactive disease and regardless of disease type, when the 2 reports occurred within a 
maximum of 1 month (κ=0.29 [remission] versus 0.31 [active disease] for CD, κ=0.15 
[remission] versus 0.27 [active disease] for UC). From this observation, we decided to calculate 
kappas for the total number of observations, irrespective of (HCP-reported) disease activity. It 
is thus important to consider that the majority of patients were stable and in remission. 
Statistical analysis  
Descriptive analyses with numbers and percentages, or means and standard deviations, 
were used to characterize the study population.  
We performed the analyses on the completed and comparable subset of items collected 
independently by HCPs and patients. As the patient self-reported questionnaire was completed 
at home, patients could freely decide on which date to complete it (i.e., immediately after 
receiving it or later). Therefore, we restricted the analyses to data collection made within a delta 
time (∆t) ranging from 0 to 2 months. Median time between the HCP report and the patient 
report was 26 days for CD (interquartile range [IQR] 11-41 days, range 0-59 days) and 26 days 
for UC (IQR 13-41 days, range 0-59 days). If a patient presented with several reports, all reports 
were included. HCP reports were spaced at least 1 year apart (HCP data collection is performed 
yearly). Agreement between patients and HCPs was assessed by using Cohen’s kappa statistic. 
We stratified the analysis by diagnosis (CD and UC). Categorical variables were treated as 
ordinal, and a quadratic weight was applied to penalize more serious disagreements. For 
complex multi-item variables (EIMs), we computed a pooled kappa in accordance with the 
method of De Vries et al.24: we averaged the observed and expected probability of agreement 
over several subitems and computed a single pooled kappa by using these 2 quantities. A pooled 
kappa was also computed to summarize overall agreement over all examined variables. For 
pooled kappa statistics, 95% confidence intervals (CIs) were obtained by using bootstrap 
resampling. 
We calculated Spearman’s rank correlation coefficients (rho) and 95% CIs to assess the 
direction and strength of the association between QoL scores and GWB. We used the whole 
patient population who had completed a self-reported questionnaire from 2012 to 2015 
(N=2453) to calculate the correlation between patient-reported GWB and QoL scores, all 
information being collected in the same questionnaire. We restricted the ∆t analyses to 0 to 2 
months to calculate the correlation between HCP-reported GWB and QoL scores. 
Statistics were produced by using STATA v.14.1 (STATA Corp., College Station, TX, 
USA) and R version 3.4.2 (2017-09-28). 
 
Ethics approval  
 Ethics approval was obtained from the regional Swiss Ethics Committees in which cohort 
participants were enrolled (Commission d’éthique du Canton de Vaud/Protocol no. 33/06). 
Results 
Patient characteristics 
 At the time of data extraction, the SIBDC comprised 3556 patients. A response rate to 
the patient questionnaires over time of around 70%, as well as delta time restriction for 
comparison with HCP data, yielded a final sample size of 1385 patients for the present analysis, 
800 with CD (58%) and 585 with UC (42%) (Table 1). About half were women (52.2%). 
Patients had a median age of 47 years and a median disease duration of 14 years. One third of 
patients with UC and two thirds of patients with CD received at least 1 anti-tumor necrosis 
factor agent during their disease course. A higher proportion of patients with CD had a history 
of EIM than did those with UC (63.1% versus 48.0%). Around two thirds of CD patients had 
ileal involvement, half experienced stenosis, and a quarter had a perianal fistula. One third of 
UC patients had extensive disease. Patients with CD had lower PCS/MCS subscores than did 
those with UC (48.6/46.2 versus 50.7/47.4, respectively). Overall, the largest deviation from 
the normal population was observed for mental scores (46.7 versus 50). IBDQ total scores and 
subscores were all lower for CD patients than for UC patients. 
 The following analyses were conducted on 2453 reports available from patients and/or 
HCPs. The number of reports that were evaluable per patient ranged from 1 to 4, with 60% of 
patients having 2 to 4 reports (Table 2). For 38% of those reports, the ∆t between patients and 
HCP reports to the SIBDC was less than or equal to 2 months. 
Agreement analyses 
The following analyses were performed on the subgroup of patients and HCP reports 
made within ∆t 0-2 months. This corresponded to 936 reports, 535 for CD patients and 401 for 
UC patients. In this analysis, 30% of all CD patients contributed with 2 to 3 observations; the 
proportion was similar among UC patients (Table 2). 
Overall agreement 
 The overall (pooled) agreement between patients and HCP reports for all considered 
items was κ=0.35 (95% CI, 0.30–0.39) for CD and κ=0.31 (95% CI, 0.24–0.38) for UC (Figure 
1).  
Agreement on individual items 
 The best, although moderate, patient/HCP agreement was found for the number of soft 
stools reported in the last week (κ=0.47) in CD patients, and for nocturnal diarrhea (κ=0.52) 
and the presence of bloody stools (κ=0.41) in UC patients. The level of agreement was low and 
unrelated to type of diagnosis regarding abdominal pain (CD: κ=0.32, UC: κ=0.37) and GWB 
(CD: κ=0.23, UC: κ=0.26). CD patients and HCPs had low agreement on the use of antidiarrheal 
medications (κ=0.36), and UC patients had low agreement with HCPs on fecal incontinence 
(κ=0.19) and antidiarrheal treatment (κ=0.18). When exploring the direction of disagreement 
in CD, we found (Figure 2) that abdominal pain was often overestimated by clinicians compared 
with that reported by patients. Indeed, more than half of the patients for whom abdominal pain 
was reported as mild or moderate-to-severe by HCPs rated their pain as none. Figure 3 shows 
that abdominal pain was more frequently reported by UC patients as being absent or less severe 
than it was by HCPs. Of the patients for whom abdominal pain was reported as being mild or 
moderate-to-severe by HCPs, 50% to 60% rated it as none. GWB was frequently rated as being 
worse by CD patients than by HCPs. Indeed, when HCPs reported GWB as well, 32% of UC 
patients rated it as being below par and 21% as poor to terrible. In contrast, UC patients tended 
to rate GWB as being better than HCPs did. We indeed observed that, when HCPs reported 
GWB as being fair, 54% of patients rated it as excellent. 
Correlation analyses 
Correlation analyses with QoL scores were performed, first on the total number of 
reports available (N=2453) for patient-reported GWB, and then on the selected subgroup of 
patient/HCP reports made within ∆t 0-2 months for HCP-reported GWB.  
The mean (SD) value of patient-reported GWB was 3.8 (1.2) in CD patients and 3.9 
(1.2) in UC patients (Table 2). HCP-reported GWB was rated as well/excellent in three quarters 
(76.9%) of CD patients and as well/excellent in one third (34.7%) of UC patients. Nearly half 
of UC patients were rated by HCPs as having poor/terrible GWB. 
Spearman’s rank correlation coefficients between GWB and QoL scores, Table 3, were 
all significant for the monotonic association, but the strength of the correlation varied 
considerably, depending on HCP and patient reports, type of disease, and QoL instrument. 
Overall, patient self-rated GWB was more strongly correlated with QoL scores than was HCP-
reported GWB, and the correlation was better for UC patients than for CD patients. When 
reported by HCPs, GWB had little correlation (rho<0.3) with the MCS subscore (rho=-0.26) 
and the IBDQ emotional function subscore (rho=-0.28) in CD patients. Although still low 
(rho<0.5), the correlation was better for CD patients at ∆t=1-2 months than at ∆t=0-1 month. 
In UC patients, correlations between HCP-reported GWB and QoL scores were better when the 
time interval between both reports was the shortest. Patient self-rated GWB correlated 
moderately to highly with QoL subscores. The highest correlation was observed with the IBDQ 
total sum score (r=0.68 for CD, r=0.70 for UC) and the lowest with the MCS subscore (r=0.49 
for CD, r=0.50 for UC). Overall, the correlation of patient self-rated GWB was better with 
IBDQ scores than with SF-36 scores.
Discussion 
Herein we presented analyses performed on real-world data collected by HCPs and 
patients in the framework of the SIBDC. Using these data, we were able to assess the level of 
agreement between patients and HCPs on the signs and symptoms used for clinical activity 
score calculations. We found that the agreement between reports was in general low – high 
agreement corresponds to a kappa above 0.6 – especially for abdominal pain and GWB. We 
also assessed the feasibility of capturing information on patients’ QoL by using a single 
question on GWB. We found that the correlation between answers to this single question and 
QoL scores was good when reported by patients but not when reported by HCPs. Patient self-
rated GWB was highly correlated with the IBDQ total sum score, indicating that the answer to 
a single and simple question could indeed be used to reflect disease-related QoL, provided that 
the question is answered by patients in their own setting. 
Two previous studies conducted by Bennebroek Evertsz et al. also made crude 
comparisons between HCP- and patient-reported items on disease activity items in CD25 and 
UC26. For CD, they found lower agreement on abdominal pain (k=0.14) but higher on GWB 
(k=0.52) than we did in our study. In their study, CD patient-reported abdominal pain was never 
scored lower than that of HCPs, which was the opposite of our results. For UC, they found 
results similar to ours, i.e., the highest level of agreement for nocturnal diarrhea (k=0.67) and 
the presence of bloody stools (k=0.63), the lowest for fecal incontinence (k=0.26); the 
agreement for GWB (k=0.49) was moderate. A positive aspect of their studies was that both 
measures were taken within a short time frame, which may have favored slightly better 
agreement than occurred with the findings of our study. On the other hand, patient reports were 
collected in the doctor’s setting, i.e., not independently in the patient’s own environment. This 
may explain why, in the Bennebroek Evertsz et al. study, better agreement on GWB was not 
achieved, although the study conditions were good. Agreement is a measure of the difference 
between HCP reports on patient signs or symptoms (i.e., made during a medical visit) and 
patient self-reports on the same parameters, but collected outside the medical practice (i.e., in 
the patient’s living environment). Both reports were independent. When “hard quantitative” or 
“objective” measures are compared, we would expect the results to be the same because they 
are both reported by the patient, once in the HCP’s environment and once in the patient’s 
environment. In the case of subjective assessments, however, e.g., well-being, the double 
mechanism of reporting (by the patient) and interpretation of this reporting (by the 
physician/HCP) might lead to disagreement. Reasons for the disagreement might be linked to 
recall bias and socially desirable responding27-29. Response to reports can also be influenced by 
many factors, including stress and fear of medical visits among patients, busy teams and work 
overload among HCPs, or other societal and cultural factors. The question here was not to 
consider whose reporting was right or wrong, but to assess, on a similar question, potential 
sources of measurement errors that could be introduced by the context in which measures were 
taken, potentially leading to over- or underestimation of activity scores. This is especially 
important for items that have high weights in score calculations. 
Recent studies have proposed the use of interim PROs in randomized controlled trials 
(RCTs)6, 7 while awaiting the development of PROs by using standards provided by the US 
Food and Drug Administration. PRO-2 and 3, including GWB and abdominal pain for CD, 
were considered reasonable information reported by patients13, hypotheses that are not 
confirmed by our data. However, these studies used patient information obtained during clinical 
trials, where the framework in which the data were collected differed from that of routine 
practice. Our data support the view that the use of PRO-2 or 3 is probably not transposable to 
real-life routine clinical practice or would require validation in this setting.  
Abdominal pain is considered by patients to be an important item for assessment13. Our 
results suggest, however, that the setting for collection of this symptom modulates patients’ 
answers. Indeed, in both CD and UC, abdominal pain was rated lower when reported by patients 
than by HCPs. We hypothesize that this difference is related to an observer bias, since patients 
seem to systematically underrate abdominal pain when they are not in front of their physician. 
One reason might be a beneficial effect of the home environment on their feeling of pain 
compared with that at the doctor’s practice. Alternatively, pain may be used to attract more of 
their doctor’s attention to other symptoms. To improve the correlation of this measure, we could 
consider collecting additional information that may be associated with abdominal pain (i.e., 
disability, stress, sleep quality, fatigue)30-32 because the question might be whether abdominal 
pain reflects a cause or a consequence of other symptoms. 
We observed that patient self-rated GWB correlated much better with SF-36 and IBDQ 
scores than did HCP-reported GWB, with some limitations for the mental health component. 
This result suggests that it may be possible to assess disease-related QoL through a unique 
question on well-being. These findings further indicate that the context in which patients answer 
subjective questioning is crucial. GWB may be modified and less reliable when the patient is 
questioned by a doctor in a setting (time pressure, waiting room oversaturation) that can further 
alter the patient’s response in unpredictable ways. We could have argued for a social desirability 
bias33, but our results showed that the most favorable answer is not found in patients’ home 
reports, but in the answers given in front of physicians, at least in CD. Our observation is, 
however, consistent with previous guidelines that reported a higher likelihood of face-to-face 
interviews to prompt positive reports about patient well-being than with self-administered 
questionnaires33. Among other factors that could be associated with GWB in patients is gender, 
which was shown to be associated with the perception of QoL34, or potential variations in the 
clinical interpretation of subjective measures of disease activity.   
One way to move highly subjective PROs outside the clinical setting would be to use 
remote or mobile tools. Several attempts have already been made in this direction, allowing 
shared data collection35, 36. Telemedicine systems that facilitate the sharing of information and 
feedback have proven to be useful in disease activity monitoring23, 37. Therefore, further 
attempts in this direction should be tested. For example, GWB could be completed by the 
patient at home on request of the treating physician, e.g., 24 hours before the medical 
appointment, so that it could be used during the consultation.  
The strength of our study was the ability to use real-life data collected through an 
ongoing cohort study. This allowed us to investigate how data, which should be collected in the 
same way as in clinical trials for decision making, could be collected in the reality of current 
practice. The other strength of our study was the unique collection of patient-reported data that 
was done in parallel with the collection of clinical data.  
Our study has some limitations. In performing agreement analyses, the ideal interval 
between clinic follow-up visit and questionnaire participation should be as short as possible. In 
our study, this limitation was compensated for by the opportunity to have independent measures 
made by the patient and the HCP. This allowed us to investigate differences according to the 
context in which data collection was made. Moreover, the large majority of patients in our study 
were in remission; therefore, we can assume a low likelihood of major changes in the patients’ 
symptoms within a 2-month time interval. Nevertheless, a previous study showed that patients 
may experience more flares than those discussed with the physician38. Therefore, we could not 
ensure that all patients were in the disease activity stage, as reflected by the sum score of the 
HCP-reported activity index.   
To bridge the gap between clinical research and practice, we need simple PROs that can 
be used in a standardized way both in RCTs and in the real-world clinical context. Our results 
show that it is possible to capture information reflecting patients’ signs, even on the basis of 
single questions. This condition is essential for routine clinical practice. However, the 
differences we observed require further research in 2 directions: first, in PRO research, which 
is already the scope of ongoing studies, and second, in assessing the feasibility and practicability 
of methods for collecting such data, particularly with respect to subjective measures in which 
the context of data collection, a proxy of known and unknown confounders, appears to have an 
impact. 
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Figure 1: Cohen’s Kappa (κ), 95% confidence intervals, for patient/HCP agreement on disease 
activity score items. Gray colors indicate ranges for κ interpretation (0-0.2: very low agreement, 
0.2-0.4: low, 0.4-0.6: moderate, 0.6-0.8: high, 0.8-1: perfect). 
 
Figure 2: Differences between CD patient/HCP ratings on abdominal pain and general well-
being.  
 
Figure 3: Differences between UC patient/HCP ratings on abdominal pain and general well-
being. 
TABLES 
Table 1: Patients’ clinical and psychometric characteristics  
 
 CD UC Total 
Number of patients 800 (57.8) 585 (42.2) 1385 
Gender 
  Male 
  Female 
 
367 (45.9) 
433 (54.1) 
 
295 (50.4) 
290 (49.6) 
 
662 (47.8) 
723 (52.2) 
Age at diagnosis (median, range) 26, 3 – 78 31, 3 – 79 28, 3 – 79 
Age (median, range) 47, 18 – 94 48, 19 – 89 47, 18 – 94 
Years of disease duration (median, range) 15, 1 – 57 13, 1 - 54 14, 1 - 57 
Therapy history 
  5-ASA 
  Steroids 
  Immunomodulators 
  Anti-TNF 
 
492 (61.5) 
701 (87.6) 
674 (84.3) 
498 (62.3) 
 
561 (95.9) 
494 (84.4) 
394 (67.4) 
211 (36.1) 
 
1053 (76.0) 
1195 (86.3) 
1068 (77.1) 
709 (51.2) 
History of EIM 505 (63.1) 281 (48.0) 786 (56.8) 
History of Perianal Fistula 214 (26.7)   
History of Stenosis 381 (47.6)   
CD disease location  
  L1 (ileal) 
  L2 (colonic) 
  L3 (ileocolonic) 
  L4 (Upper GI only) 
  Unknown/unclear 
 
247 (30.9) 
274 (24.3) 
243 (30.4) 
22 (2.8) 
14 (1.8) 
  
UC disease extension  
  Pancolitis 
  Left-sided colitis 
  Proctitis 
  Unknown/Unclear 
  
204 (34.9) 
250 (42.7) 
123 (21.0) 
8 (1.4) 
 
SF36 (mean, SD) 
  Physical Component Summary (PCS) 
  Mental Component Summary (MCS) 
 
48.6 (9.4) 
46.2 (11.3) 
 
50.7 (8.4) 
47.4 (9.9) 
 
49.5 (9.1) 
46.7 (10.7) 
IBDQ (mean, SD) 
  Bowel subscore 
  Systemic subscore 
  Emotional subscore 
  Social subscore 
Total 
 
57.3 (9.6) 
25.2 (6.1) 
66.2 (12.7) 
30.7 (5.7) 
179.5 (30.5) 
 
59.0 (9.8) 
26.0 (5.9) 
67.7 (11.7) 
31.7 (5.4) 
184.3 (29.3) 
 
58.0 (9.8) 
25.5 (6.0) 
66.8 (12.3) 
31.1 (5.6) 
181.5 (30.1) 
 
  
Table 2: Description of the number of reports available from 2012 to 2015, the ∆t between 
patient/HCP reports, and patient/HCP overall rating scores on GWB.  
 
 
 CD UC Total 
Number of Patient-reports available per patient 
  1 
  2 
  3-4 
 
322 (40.3) 
321 (40.1) 
157 (19.6) 
 
254 (43.4) 
237 (40.5) 
94 (16.1) 
 
576 (41.6) 
558 (40.3) 
251 (18.2) 
∆t between HCP/Patient reports 
  0-1 month 
  1-2 months 
Total reports (patients)with ∆t 0-2 months 
  2-4 months 
  4-6 months 
  Total 
 
318 (22.1) 
217 (15.1) 
535 (398) 
526 (36.6) 
378 (26.3) 
1439 (100.0) 
 
224 (22.1) 
177 (17.5) 
401 (310) 
355 (35.1) 
258 (25.4) 
1014 (100.0) 
 
542 (22.1) 
394 (16.1) 
936 (708) 
881 (35.9) 
636 (25.9) 
2453 (100.0) 
Patient self-rated single question on GWB (mean, 
SD) 
3.8 (1.2) 3.9 (1.2) 3.8 (1.2) 
HCP-reported GWB for ∆t <= 2months 
  Well / Excellent 
  Below par / Fair 
  Poor-terrible / Poor 
 
392 (76.9) 
87 (17.1) 
31 (6.1) 
 
132 (34.7) 
72 (18.9) 
177 (46.5) 
 
524 (58.8) 
159 (17.9) 
208 (23.3 
 
 
  
Table 3: Spearman’s rank correlation coefficient rho (95% confidence intervals) between 
ratings on GWB and QoL scores.  
 
 GWB rated by HCP GWB rated  
by P 
 0-1 months 1-2 months 0-2 months  
CROHN’S DISEASE  
   SF-36 PCS 0.30 (0.18 to 0.41) 0.47 (0.36 to 0.59) 0.38 (0.30 to 0.45) 0.55 (0.51 to 0.59) 
   SF-36 MCS 0.23 (0.11 to 0.36) 0.27 (0.15 to 0.40) 0.26 (0.17 to 0.35) 0.49 (0.45 to 0.54) 
   IBDQ Bowel 0.30 (0.20 to 0.40) 0.42 (0.31 to 0.54) 0.35 (0.28 to 0.43) 0.59 (0.55 to 0.63) 
   IBDQ Systemic 0.28 (0.17 to 0.40) 0.42 (0.30 to 0.55) 0.35 (0.28 to 0.43) 0.65 (0.61 to 0.68) 
   IBDQ Emotional 0.23 (0.12 to 0.34) 0.34 (0.22 to 0.47) 0.28 (0.20 to 0.36) 0.60 (0.56 to 0.64) 
   IBDQ Social 0.23 (0.11 to 0.34) 0.41 (0.28 to 0.53) 0.31 (0.22 to 0.39) 0.58 (0.54 to 0.62) 
   IBDQ Total 0.29 (0.19 to 0.40) 0.43 (0.31 to 0.55) 0.35 (0.28 to 0.43) 0.68 (0.64 to 0.71) 
     
ULCERATIVE COLITIS  
   SF-36 PCS 0.32 (0.19 to 0.45) 0.30 (0.16 to 0.44) 0.31 (0.21 to 0.41) 0.60 (0.55 to 0.65) 
   SF-36 MCS 0.34 (0.20 to 0.47) 0.18 (0.03 to 0.33) 0.22 (0.17 to 0.37) 0.50 (0.45 to 0.56) 
   IBDQ Bowel 0.31 (0.18 to 0.45) 0.30 (0.14 to 0.46) 0.31 (0.21 to 0.40) 0.64 (0.59 to 0.68) 
   IBDQ Systemic 0.41 (0.29 to 0.53) 0.31 (0.15 to 0.46) 0.36 (0.27 to 0.46) 0.62 (0.58 to 0.67) 
   IBDQ Emotional 0.41 (0.30 to 0.53) 0.30 (0.14 to 0.48) 0.36 (0.27 to 0.45) 0.61 (0.56 to 0.65) 
   IBDQ Social 0.34 (0.22 to 0.47) 0.34 (0.21 to 0.52) 0.35 (0.25 to 0.45) 0.60 (0.55 to 0.65) 
   IBDQ Total 0.43 (0.31 to 0.54) 0.34 (0.19 to 0.34) 0.39 (0.30 to 0.48) 0.70 (0.66 to 0.74) 
 
Interpretation of the rho value: |rho|<0.3 indicate little to no correlation, 0.5<|rho|<0.3 low 
correlation, 0.7<|rho|<0.5 moderate correlation, |rho|>0.7 high correlation. 
